<DOC>
	<DOCNO>NCT02565758</DOCNO>
	<brief_summary>This open-label dose escalation study design evaluate safety pharmacokinetics ABBV-085 determine recommend Phase 2 dose ( monotherapy combination standard therapy ) subject advance solid tumor .</brief_summary>
	<brief_title>ABBV-085 , Antibody Drug Conjugate , Subjects With Advanced Solid Cancer Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Participants advance solid tumor amenable surgical resection approve therapeutic option . 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . 3 . Participants must measurable disease per Response Evaluation Criteria In Solid Tumors ( RECIST ) version 1.1 disease evaluable assessment tumor antigen : Participants nonevaluable nonmeasurable cancer eligible confirm increase tumor antigen &gt; =2 x upper limit normal ( ULN ) . 4 . All participant must consent provide archive diagnostic formalinfixed paraffin embed ( FFPE ) tumor tissue , available . 5 . Participant adequate bone marrow , renal , hepatic cardiac function . 6 . Women childbearing potential must negative serum pregnancy test within 14 day prior initiation treatment . 1 . Participant receive anticancer therapy investigational therapy within period 21 day prior first dose ABBV085 . 2 . Uncontrolled metastases central nervous system ( CNS ) . Participants brain metastasis eligible provide show clinical radiographic stable disease least 4 week definitive therapy use steroid least 4 week prior first dose ABBV085 . 3 . Unresolved adverse event &gt; = Grade 2 prior anticancer therapy , except alopecia . 4 . Participant ongoing hemolysis . 5 . Major surgery within &lt; =28 day prior first dose ABBV085 . 6 . Clinically significant uncontrolled condition ( ) . 7 . Participant history major immunologic reaction auristatinbased /or Immunoglobulin G ( IgG ) contain agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neoplasm</keyword>
</DOC>